Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Inotek Pharmaceuticals has concluded first two of three stages of a double-masked, dose-ranging, randomized and multi-dose trial evaluating an eye drop, INO-8875 in patients suffering from glaucoma or ocular hypertension.
Subscribe to our email newsletter
The trial was designed to investigate the tolerability, safety, efficacy and pharmacokinetics of INO-8875 delivered as an eye-drop formulation in patients with primary open-angle glaucoma or ocular hypertension.
Inotek president and CEO Paul Howes said they believe that expanding the final stage of the Phase 2b study will produce a robust data package to support preparation for late-stage clinical trials and ongoing partnering discussions.